Trial Profile
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Nonacog beta pegol (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Registrational
- Acronyms paradigm 5
- Sponsors Novo Nordisk
- 26 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Aug 2021 Planned primary completion date changed from 1 Apr 2014 to 30 Nov 2023.
- 01 May 2020 Results (data cut off: October 1, 2018) assessing long-term safety and efficacy data from the paradigm 5 trial after a minimum of 5 years of follow-up and compare results with the 1-year analysis published in the Thrombosis and Haemostasis